Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Cohort A1 & A2: KTX-1001
KTX-1001 · 1 trial · 3 indications
Incidence of dose-limiting toxicity (DLTs), treatment-emergent adverse events (TEAEs), treatment-related AEs, and clinically significant changes in laboratory test results
| Arm | Type | Description |
|---|---|---|
| Cohort A (Single agent): KTX-1001 + dexamethasone | EXPERIMENTAL | Cohort A1 (single agent): KTX-1001 at RP2D1 + dex Cohort A2 (single agent): KTX-1001 at RP2D2 + dex |
| Cohort B (Mezigdomide): KTX-1001 + Mezigdomide + dex | EXPERIMENTAL | Cohort B1 (Mezigdomide): KTX-1001 at RP2D1 + Mezigdomide + dex Cohort B2 (Mezigdomide):: KTX-1001 at RP2D2 + Mezigdomide + dex |
| Cohort C (carfilzomib/KYPROLIS®): KTX-1001 + carfilzomib + dex | EXPERIMENTAL | Cohort C1 (carfilzomib/KYPROLIS®): KTX-1001 at RP2D1 + carfilzomib + dex Cohort C2 (carfilzomib/KYPROLIS®): KTX-1001 at RP2D2 + carfilzomib + dex |
| Cohort D (pomalidomide): KTX-1001 + pomalidomide + dex | EXPERIMENTAL | Cohort D (pomalidomide): KTX-1001 at RP2D2 + pomalidomide + dex |
| Name | Type | Description |
|---|---|---|
| Cohort A1 & A2: KTX-1001 | DRUG | KTX-1001: Orally for 28 days each cycle until progression. Dexamethasone: Orally once weekly |
| Cohort B1 & B2: KTX-1001+Mezigdomide | DRUG | Drug: KTX-1001: Orally for 28 days each cycle until progression Drug: Dexamethasone: Orally once weekly Drug: Mezigdomide Dexamethasone: Orally once weekly |
| Cohort C1 & C2: KTX-1001 + Carfilzomib (KYPROLIS®) | DRUG | Drug: KTX-1001: Orally for 28 days each cycle until progression Drug: Dexamethasone: Orally once weekly Drug: Carfilzomib (KYPROLIS®): IV, once weekly for 3 weeks in each 28-day cycle |
| Cohort D: KTX-1001+ pomalidomide (Pomalyst, Imnovid) | DRUG | Drug: KTX-1001: Orally for 28 days each cycle until progression Drug: Dexamethasone: Orally once a week Drug: Pomalidomide (Pomalyst, Imnovid): Orally, for 21 days in each 28-day cycle |
Key Inclusion Criteria for Dose-Expansion: * ≥ 18 years of age * ECOG score ≤ 1 * Multiple myeloma (as per IMWG) * Prior therapy for MM: Participants must have received at least 1 and up to 3 prior lines of therapy as defined by IMWG, and the following drug classes: PI, IMiD, and anti-CD38 antib...
Top 20 of 25 competitors